Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal ...Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects,such as diarrhea and colitis,which may lead to the cessation of ICIs.Although irAE gastritis is rarely reported,it may lead to serious complications such as gastrorrhagia.Furthermore,irAE gastritis is often difficult to identify early due to its diverse symptoms.Although steroid hormones and immunosuppressants are commonly used to reverse irAEs,the best regimen and dosage for irAE gastritis remains uncertain.In addition,the risk of recurrence of irAE gastritis after the reuse of ICIs should be considered.In this editorial,strategies such as early identification,pathological diagnosis,mana-gement interventions,and immunotherapy rechallenge are discussed to enable clinicians to better manage irAE gastritis and improve the prognosis of these patients.展开更多
Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal ...Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects,such as diarrhea and colitis,which may lead to the discontinuation of ICIs.展开更多
目的:探讨免疫检查点抑制剂(ICI)治疗非小细胞肺癌(NSCLC)患者发生免疫检查点抑制剂相关性肺炎(CIP)的发生情况和免疫治疗疗效的关系,分析接受ICI治疗的NSCLC患者的预后相关因素。方法:回顾性分析2020年3月至2023年3月在新疆医科大学附...目的:探讨免疫检查点抑制剂(ICI)治疗非小细胞肺癌(NSCLC)患者发生免疫检查点抑制剂相关性肺炎(CIP)的发生情况和免疫治疗疗效的关系,分析接受ICI治疗的NSCLC患者的预后相关因素。方法:回顾性分析2020年3月至2023年3月在新疆医科大学附属肿瘤医院接受ICI治疗145例NSCLC患者的临床资料,将患者分为CIP组和非CIP组,随后将发生CIP的患者分为轻度(1、2级)CIP和重度(3、4级)CIP两个亚组,通过Kaplan-Meier法比较生存曲线,分析CIP的发生及严重程度对于患者PFS及OS的影响。通过单因素及多因素COX风险比例回归模型分析与PFS和OS相关的预后因素。结果:145例患者中有26例患者出现CIP,发生率为17.93%,重度CIP发生率为3.45%。CIP组患者PFS明显长于非CIP组患者(12.3 vs 7.6个月,P<0.05),CIP组与非CIP组的OS比较差异无统计学意义(16.2 vs 15.8个月,P>0.05)。亚组分析显示,轻度CIP和重度CIP相比,PFS(12.2vs 12.9个月)及OS(16.1 vs 17.8个月)均无统计学意义(均P>0.05)。多因素COX回归分析显示,CIP[HR=0.55,95%CI(0.33,0.90),P=0.02]、免疫疗程>6个[HR=0.51,95%CI(0.31,0.85),P=0.01]是影响患者PFS的有利预后因素,免疫疗程>6个[HR=0.4,95%CI(0.18,0.88),P=0.02]是影响OS的有利预后因素。结论:CIP的发生率为17.93%,CIP的发生与PFS的延长密切相关。免疫疗程>6个是影响NSCLC患者PFS、OS的有利预后因素。展开更多
BACKGROUND As immune checkpoint inhibitors(ICIs)have become widely used in lung cancer treatment,immune-related adverse events(irAEs)warrant sufficient attention.Checkpoint inhibitor-related pneumonitis(CIP)is one of ...BACKGROUND As immune checkpoint inhibitors(ICIs)have become widely used in lung cancer treatment,immune-related adverse events(irAEs)warrant sufficient attention.Checkpoint inhibitor-related pneumonitis(CIP)is one of the most concerning adverse events as it is uncommon but life threatening.CASE SUMMARY The patient whose case is reported here experienced three episodes of CIP in a span of 4 mon.Interestingly,the three episodes of CIP involved different regions of the lung separately.Taking these pneumonitis areas together makes nearly a whole lung area.CONCLUSION This case showed that recurrent CIPs may occur repeatedly until the whole lung is involved,suggesting that the follow-up period of CIP should be long enough,and the rechallenge of ICI should be done with due caution.展开更多
BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies....BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies.CASE SUMMARY A patient with stage ⅢB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy under the guidance of second-generation sequencing. He achieved a partial response after four cycles of treatment with progression-free survival of 5 mo. Pembrolizumab was suspended due to grade 2 immunerelated pneumonia, which was resolved by oral glucocorticoids.However, disease progression was observed after immunotherapy rechallenge and anlotinib therapy. The patient had disease progression, multiorgan dysfuntion and died suddenly in October 2019.CONCLUSION The combination of immune checkpoint inhibitor, anti-angiogenic agents and chemotherapy showed effective response for advanced pleural mesothelioma, but with adverse reactions.展开更多
基金Supported by Joint Funds for the Innovation of Science and Technology,Fujian Province,China,No.2021Y9227Natural Science Foundation of Fujian Province,China,No.2023J011254+2 种基金The Science Foundation for The Excellent Youth Scholars of Fujian Provincial Health Commission,China,No.2022ZQNZD009The Special Research Funds for Local Science and Technology Development Guided by Central Government,Fujian Province,China,No.2023L3020Fujian Medical University Student Innovation and Entrepreneurship Training Project,China,No.JC2023191.
文摘Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects,such as diarrhea and colitis,which may lead to the cessation of ICIs.Although irAE gastritis is rarely reported,it may lead to serious complications such as gastrorrhagia.Furthermore,irAE gastritis is often difficult to identify early due to its diverse symptoms.Although steroid hormones and immunosuppressants are commonly used to reverse irAEs,the best regimen and dosage for irAE gastritis remains uncertain.In addition,the risk of recurrence of irAE gastritis after the reuse of ICIs should be considered.In this editorial,strategies such as early identification,pathological diagnosis,mana-gement interventions,and immunotherapy rechallenge are discussed to enable clinicians to better manage irAE gastritis and improve the prognosis of these patients.
基金Supported by the National Natural Science Foundation of China,No.81671226Natural Science Foundation of Henan Province,No.232300421047+1 种基金Science and Technology Innovation Talents in Universities of Henan Province,No.24HASTIT067Henan Province Young and Middle-aged Health Science and Technology Innovation Talent Project,No.JQRC2023001.
文摘Immune checkpoint inhibitors(ICIs)are widely used due to their effectiveness in treating various tumors.Immune-related adverse events(irAEs)are defined as adverse effects resulting from ICI treatment.Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects,such as diarrhea and colitis,which may lead to the discontinuation of ICIs.
文摘目的:探讨免疫检查点抑制剂(ICI)治疗非小细胞肺癌(NSCLC)患者发生免疫检查点抑制剂相关性肺炎(CIP)的发生情况和免疫治疗疗效的关系,分析接受ICI治疗的NSCLC患者的预后相关因素。方法:回顾性分析2020年3月至2023年3月在新疆医科大学附属肿瘤医院接受ICI治疗145例NSCLC患者的临床资料,将患者分为CIP组和非CIP组,随后将发生CIP的患者分为轻度(1、2级)CIP和重度(3、4级)CIP两个亚组,通过Kaplan-Meier法比较生存曲线,分析CIP的发生及严重程度对于患者PFS及OS的影响。通过单因素及多因素COX风险比例回归模型分析与PFS和OS相关的预后因素。结果:145例患者中有26例患者出现CIP,发生率为17.93%,重度CIP发生率为3.45%。CIP组患者PFS明显长于非CIP组患者(12.3 vs 7.6个月,P<0.05),CIP组与非CIP组的OS比较差异无统计学意义(16.2 vs 15.8个月,P>0.05)。亚组分析显示,轻度CIP和重度CIP相比,PFS(12.2vs 12.9个月)及OS(16.1 vs 17.8个月)均无统计学意义(均P>0.05)。多因素COX回归分析显示,CIP[HR=0.55,95%CI(0.33,0.90),P=0.02]、免疫疗程>6个[HR=0.51,95%CI(0.31,0.85),P=0.01]是影响患者PFS的有利预后因素,免疫疗程>6个[HR=0.4,95%CI(0.18,0.88),P=0.02]是影响OS的有利预后因素。结论:CIP的发生率为17.93%,CIP的发生与PFS的延长密切相关。免疫疗程>6个是影响NSCLC患者PFS、OS的有利预后因素。
文摘BACKGROUND As immune checkpoint inhibitors(ICIs)have become widely used in lung cancer treatment,immune-related adverse events(irAEs)warrant sufficient attention.Checkpoint inhibitor-related pneumonitis(CIP)is one of the most concerning adverse events as it is uncommon but life threatening.CASE SUMMARY The patient whose case is reported here experienced three episodes of CIP in a span of 4 mon.Interestingly,the three episodes of CIP involved different regions of the lung separately.Taking these pneumonitis areas together makes nearly a whole lung area.CONCLUSION This case showed that recurrent CIPs may occur repeatedly until the whole lung is involved,suggesting that the follow-up period of CIP should be long enough,and the rechallenge of ICI should be done with due caution.
文摘BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies.CASE SUMMARY A patient with stage ⅢB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy under the guidance of second-generation sequencing. He achieved a partial response after four cycles of treatment with progression-free survival of 5 mo. Pembrolizumab was suspended due to grade 2 immunerelated pneumonia, which was resolved by oral glucocorticoids.However, disease progression was observed after immunotherapy rechallenge and anlotinib therapy. The patient had disease progression, multiorgan dysfuntion and died suddenly in October 2019.CONCLUSION The combination of immune checkpoint inhibitor, anti-angiogenic agents and chemotherapy showed effective response for advanced pleural mesothelioma, but with adverse reactions.